Life science companies' ability to capture value from their investments is critical to the success of the industry.
I can't comment specifically on UPOV 91, but that element has been very critical to the new varieties that have been developed, to the industry's ability to combat diseases, to improving yields, and to improving oil quality. Life science companies can continue to make the investments they do because they capture the benefits of those investments.